<DOC>
	<DOCNO>NCT02219893</DOCNO>
	<brief_summary>The purpose study phase I/II clinical trial ass safety toxicity intraperitoneally administer MOC31PE immunotoxin , give 1.postoperative day cytoreductive surgery ( CRS ) Hyperthermic Intraperitoneal Chemotherapy ( HIPEC ) peritoneal metastasis colorectal cancer ( CRC ) .</brief_summary>
	<brief_title>Immunotoxin Peritoneal Carcinomatosis- ImmunoPeCa Trial</brief_title>
	<detailed_description>MOC31PE immunotoxin previously evaluate phase I clinical study involve patient advance EpCAM positive carcinoma ass safety tolerability profile pharmacokinetic behavior compound . In study , compound administer intravenously well tolerate . MOC31PE evaluate parameter new phase I/II clinical trial , drug administer intraperitoneally patient peritoneal metastasis EpCAM positive colorectal carcinoma .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Immunotoxins</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<criteria>Inclusion criterion : Histologically verify EpCAM positive colorectal cancer Ambulatory Eastern Cooperative Oncology Group ( ECOG ) performance status 01 time surgery At least 18 year age Suspected isolated peritoneal carcinomatosis upon radiologic workup Complete cytoreduction surgery mitomycin C give standard HIPEC procedure Peritoneal Cancer Index ( PCI ) ≤ 20 Laboratory value inclusion : Absolute neutrophil count ( ANC ) &gt; 1.5 x 10^9/L Platelets &gt; 100 x 10^9/L Hb &gt; 9g/dL Creatinine ≤ 2x upper limit normal Bilirubin &lt; 2.0x upper limit normal Aspartate aminotransferase ( AST ) Alanine aminotransferase ( ALT ) ≤ 2 . 5x upper limit normal Albumin level &gt; 30 g/L International normalise ratio ( INR ) &lt; 1.3 Signed inform consent expect cooperation respect treatment followup must obtain document accord International Conference Harmonisation Good clinical Practice ( ICH GCP ) , national/local regulation . Exclusion criterion : Other synchronous metastatic lesion . Patients may include curative resection metastatic CRC disease 2 year prior inclusion relapse location detect . History prior malignant disease last 3 year , except adequately treat carcinoma cervix basal squamous cell skin cancer . History central nervous system ( CNS ) bone metastases Significant cardiac medical illness would limit activity survival , severe congestive heart failure , unstable angina , serious cardiac arrhythmia History liver disease include Hepatitis B C infection Chemotherapy/radiation therapy major surgery within last 4 week start treatment BMI &gt; 35 Pregnant breastfeeding patient Alcohol drug abuse Use drug influence hepatic function ( e.g . phenytoin phenobarbital ) Use anticoagulants Any reason , opinion investigator , patient participate study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Peritoneal Carcinomatosis</keyword>
	<keyword>Peritoneal Metastasis</keyword>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Cytoreductive surgery</keyword>
	<keyword>HIPEC</keyword>
	<keyword>Intraperitoneal treatment</keyword>
	<keyword>Immunotoxin</keyword>
	<keyword>MOC31PE</keyword>
</DOC>